Watch our latest webinar to learn how the TissueCypher® Barrett’s Esophagus Assay may be an important new precision medicine tool for today’s Barrett’s esophagus expert.
Three million people in the U.S. have Barrett's Esophagus, a known precursor to esophageal cancer. Until now, identifying which patients are at greatest risk for esophageal cancer has been impossible. Cernostics is looking to change that… Learn how
Two Independent Peer-Reviewed Studies Validate Cernostics’ TissueCypher® Barrett’s Esophagus Assay (TissueCypher®) to Accurately Predict Progression to Esophageal Cancer in Patients with Barrett’s Esophagus... Read More
09/10/2020
Cernostics and Deciphex Announce Strategic Collaboration to Develop AI-Based Histology Diagnostics and Prognostics for Barrett’s Esophagus... Read More
06/25/2020
Cernostics Announces Blinded, Independent Validation of TissueCypher ® Performance for Predicting Risk of Progression to Esophageal Cancer in Patients with Non-Dysplastic BE... Read More